D. Matthew Walentiny

Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo

Jonathan Z. Long, Daniel K. Nomura, Robert E. Vann et al. · Proceedings of the National Academy of Sciences · 2009 · 385 citations · Full text

Psychopharmacology, Endocannabinoid Crosstalk, Pharmacotherapy +22

<i>In vivo</i> characterization of the highly selective monoacylglycerol lipase inhibitor <scp>KML</scp>29: antinociceptive activity without cannabimimetic side effects

Bogna M. Ignatowska‐Jankowska, Sudeshna Ghosh, Molly S. Crowe et al. · British Journal of Pharmacology · 2013 · 125 citations · Full text

Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances

Neil B. Varshneya, D. Matthew Walentiny, L Moisă et al. · Neuropharmacology · 2019 · 53 citations · Full text

Fentanyl-related Substances, Health Sciences, Fentanyl +8

Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents

D. Matthew Walentiny, Robert E. Vann, Jonathan A. Warner et al. · Psychopharmacology · 2010 · 49 citations · Full text

Cannabis Use, Psychoactive Drug, Addiction +12

Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist

Jenny L. Wiley, C. S. Breivogel, Anu Mahadevan et al. · European Journal of Pharmacology · 2010 · 32 citations · Full text

Cannabis Use, Molecular Pharmacology, Psychoactive Drug +10